By Stephen Nakrosis 
 

Blueprint Medicines Corp. on Wednesday said the Food and Drug Administration has approved Ayvakit to treat adult patients with advanced systemic mastocytosis.

The approval covers Ayvakit, or avapritinib, for the treatment of advanced systemic mastocytosis, "including aggressive SM, SM with an associated hematological neoplasm and mast cell leukemia" the company said.

Advanced systemic mastocytosis can damage organs due to the accumulation of mast cells, a type of white blood cell.

The company said it will host a live webcast beginning at 4:30 p.m. EDT to discuss the FDA approval.

 

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

June 16, 2021 16:36 ET (20:36 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Jun 2021 to Jul 2021 Click Here for more Blueprint Medicines Charts.
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Jul 2020 to Jul 2021 Click Here for more Blueprint Medicines Charts.